Bullish indicating open at $55-$60, IPO prices at $37
SEATTLE—Remmel H. Lawrence, a director at Atossa Therapeutics Inc. (NASDAQ:ATOS), has acquired 10,000 shares of the company’s common stock, according to a recent SEC filing. The purchase, completed on March 26, 2025, was executed at a price of $0.70 per share, amounting to a total transaction value of $7,000. The acquisition comes as the stock trades near its 52-week low, having declined over 53% in the past six months, according to InvestingPro data.
Following this transaction, Lawrence now holds a total of 10,257 shares directly. This acquisition reflects his continued investment in the Seattle-based pharmaceutical company, which specializes in the development of novel therapeutics for breast cancer and other breast conditions. With a market capitalization of $90.24 million, the company maintains strong liquidity with a current ratio of 14.99, though InvestingPro analysis reveals 8 additional key financial metrics and insights available to subscribers.
The filing also notes a reverse stock split of Atossa’s common stock at a ratio of 12:1, effective April 2018. Lawrence’s total holdings include 11 shares owned by his spouse, which he disclaims beneficial ownership of, except to the extent of his pecuniary interest in those shares.
In other recent news, Atossa Genetics announced its fourth-quarter and full-year financial results for 2024, reporting an earnings per share (EPS) of -0.04, which exceeded the forecasted -0.065. This better-than-expected performance was attributed to disciplined spending and a focus on their lead program, Z-endoxifen, targeting metastatic breast cancer (mBC). The company reduced its net loss to $25.5 million from $30.1 million in 2023, with operating expenses decreasing to $27.6 million from $31.4 million the previous year. Research and development expenses also saw a reduction, contributing to this financial improvement.
Atossa Genetics is prioritizing the development of Z-endoxifen, with plans to initiate a new trial in 2025 and engage with the FDA. H.C. Wainwright maintained its Buy rating for Atossa, with a price target of $7.00, reflecting confidence in the company’s strategic focus. The firm highlighted the potential of Z-endoxifen in treating mBC, emphasizing its promise in clinical trials. Additionally, Atossa plans to expand its market presence in the U.S. initially, with global expansion projected for 2026. These developments indicate Atossa’s strategic emphasis on advancing its breast cancer treatment program.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.